148 related articles for article (PubMed ID: 9468020)
1. Astatine-211-labeled biotin conjugates resistant to biotinidase for use in pretargeted radioimmunotherapy.
Foulon CF; Alston KL; Zalutsky MR
Nucl Med Biol; 1998 Feb; 25(2):81-8. PubMed ID: 9468020
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and preliminary biological evaluation of (3-iodobenzoyl)norbiotinamide and ((5-iodo-3-pyridinyl)carbonyl)norbiotinamide: two radioiodinated biotin conjugates with improved stability.
Foulon CF; Alston KL; Zalutsky MR
Bioconjug Chem; 1997; 8(2):179-86. PubMed ID: 9095358
[TBL] [Abstract][Full Text] [Related]
3. Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate.
Reist CJ; Foulon CF; Alston K; Bigner DD; Zalutsky MR
Nucl Med Biol; 1999 May; 26(4):405-11. PubMed ID: 10382844
[TBL] [Abstract][Full Text] [Related]
4. Preparation and in vivo evaluation of linkers for 211At labeling of humanized anti-Tac.
Yordanov AT; Garmestani K; Zhang M; Zhang Z; Yao Z; Phillips KE; Herring B; Horak E; Beitzel MP; Schwarz UP; Gansow OA; Plascjak PS; Eckelman WC; Waldmann TA; Brechbiel MW
Nucl Med Biol; 2001 Oct; 28(7):845-56. PubMed ID: 11578907
[TBL] [Abstract][Full Text] [Related]
5. 211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation.
Larsen RH; Murud KM; Akabani G; Hoff P; Bruland OS; Zalutsky MR
J Nucl Med; 1999 Jul; 40(7):1197-203. PubMed ID: 10405142
[TBL] [Abstract][Full Text] [Related]
6. Reagents for astatination of biomolecules. 2. Conjugation of anionic boron cage pendant groups to a protein provides a method for direct labeling that is stable to in vivo deastatination.
Wilbur DS; Chyan MK; Hamlin DK; Vessella RL; Wedge TJ; Hawthorne MF
Bioconjug Chem; 2007; 18(4):1226-40. PubMed ID: 17583925
[TBL] [Abstract][Full Text] [Related]
7. Preparation and biological evaluation of an astatine-211 labeled biotin conjugate: biotinyl-3-[211 At]astatoanilide.
Foulon CF; Schoultz BW; Zalutsky MR
Nucl Med Biol; 1997 Feb; 24(2):135-43. PubMed ID: 9089706
[TBL] [Abstract][Full Text] [Related]
8. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy.
Zalutsky MR; Vaidyanathan G
Curr Pharm Des; 2000 Sep; 6(14):1433-55. PubMed ID: 10903402
[TBL] [Abstract][Full Text] [Related]
9. Vascular-targeted radioimmunotherapy with the alpha-particle emitter 211At.
Kennel SJ; Mirzadeh S; Eckelman WC; Waldmann TA; Garmestani K; Yordanov AT; Stabin MG; Brechbiel MW
Radiat Res; 2002 Jun; 157(6):633-41. PubMed ID: 12005541
[TBL] [Abstract][Full Text] [Related]
10. Biotin reagents in antibody pretargeting. 6. Synthesis and in vivo evaluation of astatinated and radioiodinated aryl- and nido-carboranyl-biotin derivatives.
Wilbur DS; Hamlin DK; Chyan MK; Kegley BB; Quinn J; Vessella RL
Bioconjug Chem; 2004; 15(3):601-16. PubMed ID: 15149189
[TBL] [Abstract][Full Text] [Related]
11. Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system.
Goodwin DA; Meares CF; Osen M
J Nucl Med; 1998 Oct; 39(10):1813-8. PubMed ID: 9776294
[TBL] [Abstract][Full Text] [Related]
12. Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator.
Su FM; Beaumier P; Axworthy D; Atcher R; Fritzberg A
Nucl Med Biol; 2005 Oct; 32(7):741-7. PubMed ID: 16243650
[TBL] [Abstract][Full Text] [Related]
13. Comparative tissue distribution in mice of the alpha-emitter 211At and 131I as labels of a monoclonal antibody and F(ab')2 fragment.
Garg PK; Harrison CL; Zalutsky MR
Cancer Res; 1990 Jun; 50(12):3514-20. PubMed ID: 2340501
[TBL] [Abstract][Full Text] [Related]
14. (211)At-labeled and biotinylated effector molecules for pretargeted radioimmunotherapy using poly-L- and poly-D-Lysine as multicarriers.
Lindegren S; Karlsson B; Jacobsson L; Andersson H; Hultborn R; Skarnemark G
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3873S-9S. PubMed ID: 14506185
[TBL] [Abstract][Full Text] [Related]
15. The development of a [211AT]-astatinated endoradiotherapeutic drug: part IV--late radiation effects.
Brown I; Mitchell JS
Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1177-83. PubMed ID: 9539575
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of 99mTc/99Tc-MAG3-biotin conjugates for antibody pretargeting strategies.
van Gog FB; Visser GW; Gowrising RW; Snow GB; van Dongen GA
Nucl Med Biol; 1998 Oct; 25(7):611-9. PubMed ID: 9804042
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biodistribution of 211At-labeled, biotinylated, and charge-modified poly-L-lysine: evaluation for use as an effector molecule in pretargeted intraperitoneal tumor therapy.
Lindegren S; Andersson H; Jacobsson L; Bäck T; Skarnemark G; Karlsson B
Bioconjug Chem; 2002; 13(3):502-9. PubMed ID: 12009939
[TBL] [Abstract][Full Text] [Related]
18. Biodistribution of 6-[211At]astato-2-methyl-1,4-naphthoquinol bis(diphosphate salt) and 211At- in mice with a transplanted rectal adenocarcinoma.
Brown I; Carpenter RN; Mitchell JS
Int J Appl Radiat Isot; 1984 Sep; 35(9):843-7. PubMed ID: 6480147
[TBL] [Abstract][Full Text] [Related]
19. Biotin reagents for antibody pretargeting. Synthesis, radioiodination, and in vitro evaluation of water soluble, biotinidase resistant biotin derivatives.
Wilbur DS; Hamlin DK; Pathare PM; Weerawarna SA
Bioconjug Chem; 1997; 8(4):572-84. PubMed ID: 9258458
[TBL] [Abstract][Full Text] [Related]
20. Sequential radioimmunotherapy with 177Lu- and 211At-labeled monoclonal antibody BR96 in a syngeneic rat colon carcinoma model.
Eriksson SE; Elgström E; Bäck T; Ohlsson T; Jensen H; Nilsson R; Lindegren S; Tennvall J
Cancer Biother Radiopharm; 2014 Aug; 29(6):238-46. PubMed ID: 24971673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
